A5050100388- Multiple Sclerosis Research Studies
- Peripheral Neuropathies and Disorders
- Rheumatoid Arthritis Research and Therapies
- Polyomavirus and related diseases
- Systemic Lupus Erythematosus Research
- Herpesvirus Infections and Treatments
- Fibromyalgia and Chronic Fatigue Syndrome Research
- Autoimmune and Inflammatory Disorders Research
- Cytomegalovirus and herpesvirus research
- Growth Hormone and Insulin-like Growth Factors
- Metabolism and Genetic Disorders
- Acute Lymphoblastic Leukemia research
- Pancreatic function and diabetes
- Systemic Sclerosis and Related Diseases
- Amyotrophic Lateral Sclerosis Research
- Cytokine Signaling Pathways and Interactions
- Renal function and acid-base balance
- Ion Transport and Channel Regulation
- Diet and metabolism studies
- Immunotherapy and Immune Responses
- Viral Infections and Immunology Research
- Metabolism, Diabetes, and Cancer
- Ocular Diseases and Behçet’s Syndrome
- Otitis Media and Relapsing Polychondritis
- Neuroendocrine Tumor Research Advances
University of Rochester
2015-2025
Rocky Vista University
2025
University of Colorado Anschutz Medical Campus
2021-2025
University of Rochester Medical Center
2013-2024
Florida College
2024
University of Florida
1984-2024
Centennial Medical Center
2024
Southern Hills Medical Center
2024
RELX Group (Netherlands)
2023
Wayne State University
2009-2022
Accurate clinical course descriptions (phenotypes) of multiple sclerosis (MS) are important for communication, prognostication, design and recruitment trials, treatment decision-making. Standardized published in 1996 based on a survey international MS experts provided purely phenotypes data consensus at that time, but imaging biological correlates were lacking. Increased understanding its pathology, coupled with general concern the original descriptors may not adequately reflect more...
2This research was supported by U. S. Public Health Service grants 5-MO1-FR00094 CLR from the Division of Research Facilities and Resources, GRS-FR 5394 3Work done during term Postdoctoral Fellowship 5-F2-AM- 28,805. Current address: Metabolism Division, Department Medicine, Washington University School St. Louis, Missouri 4From Subdepartment Endocrinology Metabolism, Surgery, Albany Medical College, Center Hospital, Albany, New York
It has been suggested that elevated levels of insulin or insulin-like growth factors (IGFs) play a role in the development diabetic vascular complications. Previously, we have shown differential response to between cells from retinal capillaries and large arteries with former being much more responsive. In present study, characterized receptors growth-promoting effect insulinlike factor I (IGF-I) multiplication-stimulating activity (MSA, an IGF-II) on endothelial pericytes calf smooth muscle...
<b><i>Background:</i></b> Interferon β-1a (IFNβ-1a, Avonex) is efficacious in relapsing forms of MS. Studies other IFNβ preparations secondary progressive MS (SPMS) yielded conflicting results. This study was undertaken to determine whether IFNβ-1a slowed disease progression SP-MS. <b><i>Methods:</i></b> A total 436 subjects with SPMS and Expanded Disability Status Scale (EDSS) score 3.5 6.5 were randomized receive (60 μg) or placebo by weekly intramuscular injection for 2 years. The primary...
Abstract Objective A previous phase 3 study showed significant improvement in walking ability multiple sclerosis (MS) patients treated with oral, extended‐release dalfampridine (4‐aminopyridine) 10mg twice daily. The current was designed to confirm efficacy and further define safety pharmacodynamics. Methods This a 39‐center, double‐blind trial definite MS of any course type. Participants were randomized 9 weeks treatment (10mg daily; n = 120) or placebo (n 119). Response defined as...
<h3>Background:</h3> Due to a heightened risk of progressive multifocal leukoencephalopathy (PML) with increased natalizumab exposure, some physicians interrupt treatment patients multiple sclerosis (MS) despite lack data regarding the safety interruption, rate and severity MS disease activity return after or alternative strategies. <h3>Objectives:</h3> To determine effects interruption on clinical MRI measures in relapsing MS. <h3>Methods:</h3> Clinical relapses gadolinium-enhanced (Gd+)...
There are limited treatments for progressive multiple sclerosis. Ibudilast inhibits several cyclic nucleotide phosphodiesterases, macrophage migration inhibitory factor, and toll-like receptor 4 can cross the blood-brain barrier, with potential salutary effects in
To determine the test-retest reliability of strength and fatigue measurements in patients with MS healthy control subjects, to examine associations among motor fatigue, strength, ambulatory impairment patients.Motor defined as loss maximal capacity generate force during exercise, weakness are common MS.Twenty 20 age- sex-matched subjects participated study. Test-retest was assessed two identical testing sessions, separated by 3 5 days. Maximal voluntary isometric determined fixed myometry...
In a randomized, placebo-controlled, double-blind study, glatiramer acetate (Copaxone®) reduced the relapse rate and slowed accumulation of disability for patients with relapsing-remitting multiple sclerosis. Of original 251 randomized to receive or placebo, 208 chose continue in an open-label study all receiving active drug. The majority cohort continues by daily subcutaneous injection are evaluated at 6-month intervals during suspected relapse. data reported here from approximately 6 years...
The ongoing US Glatiramer Acetate (GA) Trial is the longest evaluation of continuous immunomodulatory therapy in relapsing—remitting multiple sclerosis (RRMS). objective this study was to evaluate up 15 years GA as a sole disease-modifying therapy. Two hundred and thirty-two patients received at least one dose since initiation 1991 (mITT cohort), 100 (43%, Ongoing cohort) continued February 2008. Patients were evaluated every 6 months using Expanded Disability Status Scale (EDSS). Mean...
<b>Objective</b> To evaluate the efficacy of 4-aminopyridine sustained release (4AP SR) (fampridine, EL-970) using quantitative measures motor function in multiple sclerosis (MS) patients. <b>Background</b> In vitro, 4AP improves conduction through demyelinated axons. A previous multicenter trial SR Expanded Disability Status Scale (EDSS) as primary outcome was unable to establish clinical efficacy. <b>Design/Methods</b> Ten MS patients with stable deficits (EDSS 6.0–7.5) were given 17.5 mg...
<b>Objective: </b> To examine the efficacy and safety of three different doses sustained-release fampridine in people with multiple sclerosis (MS). <b>Method: This multicenter, randomized, double-blind, placebo-controlled, parallel-group study recruited 206 participants at 24 centers United States Canada. After a single-blind, 2-week placebo run-in, were randomly assigned to receive (10, 15, or 20 mg twice daily) for 15 weeks. The primary variable was percent change walking speed based on...
Background: Multiple sclerosis (MS) is the leading cause of neurological disability among young and middle-aged adults. One most devastating consequences MS in this relatively population group unemployment. Although certain demographic disease factors have been associated with employment, few studies examined contribution person-specific factors, such as personality. Objective: The goal study was to determine extent which personality, demographics, clinical measures contribute unemployment...
Objective To determine the safety of sustained-release 4-aminopyridine in subjects with mutiple sclerosis (MS) and to examine dose-related efficacy up 40 mg twice daily. Method Multicenter, randomized, double-blind, placebo-controlled, study. Following a 4-week baseline peroid, were randomly assigned receive Fampridine-SR (n=25, doses from 10 daily, increasing 5 increments weekly) or placebo (n=11). A battery assessments was performed weekly, including MS Functional Composite (MSFC), fatigue...
<h3>Objectives:</h3> Report long-term safety and effectiveness of natalizumab over 240 weeks in the prospective, observational, open-label Safety TYSABRI Re-dosing Treatment (STRATA) Study. <h3>Methods:</h3> Patients (N = 1,094) previously enrolled multiple sclerosis clinical trials received 300 mg IV every 4 weeks, up to weeks. Serious adverse events, Expanded Disability Status Scale (EDSS) scores, annualized relapse rates were analyzed. <h3>Results:</h3> At data cutoff (February 9, 2012),...
Vitamin D insufficiency is associated with risk of multiple sclerosis (MS) relapse; whether supplementation influences prognosis unknown. The to Ameliorate MS (VIDAMS) trial aimed determine if high dose (5000 International Units (IU)/day) versus low (600 IU/day) vitamin D3, added daily glatiramer acetate (GA), reduced the clinical relapse in people established relapsing remitting (RRMS) over 96 weeks.VIDAMS a randomised, phase 3, double-blind, multi-centre, controlled conducted at sixteen...